Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022047575 - MODIFIED CORONAVIRUS STRUCTURAL PROTEIN

Publication Number WO/2022/047575
Publication Date 10.03.2022
International Application No. PCT/CA2021/051201
International Filing Date 31.08.2021
IPC
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/295 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61P 37/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C07K 14/11 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
CPC
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C07K 14/11
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Applicants
  • MEDICAGO INC. [CA]/[CA]
Inventors
  • LAVOIE, Pierre-Olivier
  • D'AOUST, Marc-Andre
Agents
  • ZIESCHE, Sonia
  • KINGWELL, Brian
  • WILKE, Mark
  • THORNE, Lisa
  • RIPLEY, Roch
  • LEE, Brian
  • SALISBURY, Clare
Priority Data
63/073,32701.09.2020US
63/211,71617.06.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
(FR) PROTÉINE STRUCTURALE DE CORONAVIRUS MODIFIÉE
Abstract
(EN) Modified coronaviras spike (S)-protein, virus-like particle (VLPs) comprising the modified S protein and nucleic acids encoding modified S protein are provided. Methods for modified S-protein and VLP production in a host or host cell are also described. The modified S-protein may comprise a transmembrane domain (TM) or portion of a TM, and a cytosolic tail (CT) or of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein and wherein the TM or portion of the TM is heterologous to the CT or portion of the CT. In addition a method for inducing immunity to a coronaviras infection in a subject, comprising administering a composition comprising the modified coronaviras (S)-protein or VLP to the subject is described.
(FR) Une protéine de spicule (S) de coronavirus modifiée, une particule pseudovirale (PPV) comprenant la protéine S modifiée et des acides nucléiques codant la protéine S modifiée. Des procédés de production de protéine S modifiée et de PPV dans un hôte ou une cellule hôte sont également décrits. La protéine S modifiée peut comprendre un domaine transmembranaire (TM) ou une partie d'un TM, et une queue cytosolique (CT) ou une partie d'une CT, la CT ou la partie de CT étant dérivée d'une protéine hémagglutinine de la grippe (HA), et la TM ou la partie de TM étant hétérologue à la CT ou à la partie de CT. En outre un procédé pour induire une immunité contre une infection par un coronavirus chez un sujet, comprenant l'administration d'une composition comprenant la protéine S de coronavirus modifiée ou la PPV au sujet est décrit.
Related patent documents
Latest bibliographic data on file with the International Bureau